Drugs / Fluzone High-Dose vaccine
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04109222 | Sep → Dec 2019 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 4 | NCT03617523 | Sep → Nov 2018 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 4 | NCT03308825 | Sep → Nov 2017 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fluzone High-Dose vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03308825 ↗ |
| Modality | Vaccine | “Fluzone High-Dose vaccine” NCT03308825 ↗ |
| Route | Intramuscular | “received a 0.5-mL dose of Fluzone High-Dose vaccine, intramuscularly” NCT03308825 ↗ |